STEMRIM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 419 JPY | -7.51% |
|
-9.50% | -27.51% |
| 09/05 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
| 13/03 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 16Cr | - | - | - | |||
| 9.19TCr | ||||||
| 3.87TCr | ||||||
| 3.28TCr | ||||||
| 2.67TCr | ||||||
| 1.53TCr |
- Stock Market
- Equities
- 4599 Stock
- Charts StemRIM
- Sector Chart
